VRTX241227P467500
- 57.60
- +2.14+3.86%
Vertex Pharmaceuticals Newsroom
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $460
Truist has lowered the Vertex Target Price to 460 dollars.
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $430 to $525
RBC Capital Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Buy by Truist Securities
TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418
Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $500
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $500 From $503, Keeps Overweight Rating
Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $430 From $426, Keeps Sector Perform Rating
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $535
Barclays Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals: Buy Rating Despite LSR Trial Setback, Future Prospects Remain Strong
Barclays Adjusts Vertex Pharmaceuticals Price Target to $418 From $509, Maintains Equalweight Rating
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $520
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals (VRTX.US) pain relief medication faces the "placebo effect" and has its rating downgraded by Oppenheimer.